Private equity firms Nordic Capital and Permira have jointly launched a EUR 3 billion (approx. USD 3.26 billion) bid to acquire Danish vaccine manufacturer Bavarian Nordic. The offer, which values each share at EUR 95, represents a significant premium over the company’s recent trading price.

The firms said the deal would accelerate Bavarian Nordic’s growth and innovation in vaccine development, particularly in infectious diseases and immunotherapy. Bavarian Nordic, known for its smallpox and mpox (monkeypox) vaccines, has gained global attention for its role in supplying critical vaccines during public health emergencies.

The acquisition proposal is currently under review by Bavarian Nordic’s board, which will evaluate the financial and strategic merits of the bid. If accepted, the deal could mark one of the largest healthcare buyouts in Europe this year and signal continued investor interest in vaccine and biologics manufacturing firms.